An Iteratively Adapted Transdiagnostic Prevention Program for Diverse High School Settings (U-PEACE): Protocol for a Randomized Controlled Trial
Abstract
Background: Despite many adolescents experiencing mental health concerns, a substantial portion lack access to evidence-based treatments (EBTs) for psychopathology; this issue is magnified for adolescents belonging to communities considered marginalized. One way to ameliorate this is by adapting existent EBTs-typically delivered in research settings-so that they are feasible and scalable in adolescent settings, such as high schools. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents may be particularly suited for this purpose due to its transdiagnostic, modular approach and its focus on adolescent clients.
Objective: This study aimed to iteratively adapt and implement the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents in 3 Title 1 high schools, with a focus on feasibility and scalability of the intervention in diverse high school settings.
Methods: For initial adaptation, members of participating high school communities will be presented with original, unadapted intervention materials and asked to provide qualitative feedback on how to make the program more appropriate and feasible for their schools (aim 1). After initial adaptations are implemented, an open-trial pilot case series will assess the appropriateness and feasibility of the resulting program: the Unified Protocol for Emotional and Academic Challenges in Education (aim 2). Initial outcome data and qualitative feedback from pilot case…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.